<DOC>
	<DOCNO>NCT00157339</DOCNO>
	<brief_summary>Phase 3 , open-label , randomize study evaluate safety efficacy Lilly/Alkermes inhale insulin system compare injected insulin type 1 type 2 diabetes patient asthma COPD . Patients treat 12 month 2 month follow period .</brief_summary>
	<brief_title>Safety Efficacy Inhaled Insulin Patients With Diabetes Asthma COPD</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Type 1 type 2 diabetes asthma COPD Current smoking habit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>